Dexamethasone or hydrocortisone in COVID-19?

To the Editor: We read with interest the article by Chatterjee et al,¹ who provided an overview of the use of corticosteroids in patients with novel coronavirus disease 2019 (COVID-19). The authors discussed the best available evidence at the time of their writing regarding the outcomes in hospitalized patients with COVID-19 who received corticosteroids. However, with the publication of more randomized trials plus a meta-analysis by the World Health Organization (WHO)² on the use of corticosteroids in patients with CO-VID-19, we wish to complement the authors' discussion to elaborate on the relationship between pharmacodynamic profiles of hydrocortisone and dexamethasone and their respective efficacy in patients with COVID-19.

From the subgroup pooled analysis by WHO to determine the association between corticosteroid use and 28-day all-cause mortality rates in COVID-19 patients, there were no mortality benefits detected from the use of hydrocortisone, whereas dexamethasone significantly reduced the odds of all-cause death at 28 days.²

This is consistent with pharmacodynamic observations. Hydrocortisone has a lower affinity for the glucocorticoid receptor compared with dexamethasone. The reported log relative receptor affinities for hydrocortisone and dexamethasone were 0.95 and 2.0, respectively.³ In addition, hydrocortisone demonstrates less inhibition of proinflammatory transcription factors than dexamethasone. For example, hydrocortisone inhibited tumor necrosis factor alpha-induced nuclear factor kappa B activation less than dexamethasone—the half-maximal inhibitory concentrations [IC50] for nuclear factor kappa inhibition were 15.52 nM and 2.93 nM, respectively.⁴ The same is observed for nongenomic activity, for which hydrocortisone demonstrates lower potency: hydrocortisone had less inhibition of the release of prostaglandin E2 (PGE2) compared with dexamethasone (the IC50s for PGE2 release were 750 nM and 20 nM, respectively).⁵ Both nuclear factor kappa B activation and PGE2 release play significant roles in the hyperinflammatory and immune responses in COVID-19.

For these reasons, along with its longer biological half-life and lesser mineralocorticoid activity, dexamethasone should be favored over hydrocortisone in patients with COVID-19 who need treatment with systemic corticosteroids.

Chia Siang Kow

School of Postgraduate Studies International Medical University Kuala Lumpur, Malaysia

Syed Shahzad Hasan School of Biomedical Sciences & Pharmacy University of Newcastle Callaghan, Australia

REFERENCES

- Chatterjee K, Wu CP, Bhardwaj A, Siuba M. Steroids in COVID-19: an overview. Cleve Clin J Med 2020 Aug 20. doi:10.3949/ccjm.87a.ccc059
- The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020 Sep 2. doi:10.1001/jama.2020.17023.
- Mager DE, Moledina N, Jusko WJ. Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation. J Pharm Sci 2003; 92(7):1521–1525. doi:10.1002/jps.10402
- Cechin SR, Buchwald P. Effects of representative glucocorticoids on TNFα- and CD40L-induced NF-κ activation in sensor cells. Steroids 2014; 85:36–43. doi:10.1016/j.steroids.2014.04.003
- Croxtall JD, van Hal PT, Choudhury Q, Gilroy DW, Flower RJ. Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br J Pharmacol. 2002; 135(2):511–519. doi:10.1038/sj.bjp.0704474

doi:10.3949/ccjm.87c.12005